Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867420 · ClinicalTrials.gov registry record · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
A Phase 1 study of Advanced Solid Tumors, sponsored by AskGene Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 594
- Enrollment target
- 4
- Study locations
NCT05867420: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by AskGene Pharma.
NCT05867420 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by AskGene Pharma. The registered enrollment target is 594 participants, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (205% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05867420, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by AskGene Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 594 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
Primary Outcome
To evaluate the safery of ASKG915 in subjects.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Fruquintinib
- BIOLOGICAL ASKG915
- DRUG Paclitaxel + Bevacizumab
Study Locations (4)
New York
- Columbia University Irving Medical Center - New York
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Beijing Municipality
- Peking University Cancer Hospital - Beijing
Shanghai Municipality
- Fudan University Shanghai Cancer Center - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2023-08-02 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
What NCT05867420 shows while recruiting
NCT05867420 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (205% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT05867420 reports a single indexed study location in New York, Pennsylvania, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT05867420 about?
NCT05867420 is a clinical study titled "A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.". The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
What is the current status of trial NCT05867420?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 594 participants. The study started on 2023-08-02. Estimated completion is 2028-06-30.
What conditions does trial NCT05867420 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05867420?
The interventions under investigation include: Docetaxel (DRUG), Fruquintinib (DRUG), ASKG915 (BIOLOGICAL), Paclitaxel + Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05867420?
This trial is sponsored by AskGene Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05867420 being conducted?
This trial has 4 study locations across New York, Pennsylvania, Beijing Municipality, Shanghai Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05867420's enrollment target sits among peer trials
594 8th of 144 higher than 137 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- NCT06892548 · 594 participants · Phase 1
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI